Rhythm Pharmaceuticals, INC

Rhythm Pharmaceuticals announced robust second quarter 2026 financial results, driven by strong IMCIVREE sales and encouraging preliminary data from its RM-718 Phase 2 trial.

Rhythm Pharmaceuticals shareholders re-elected two directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Rhythm Pharmaceuticals announced positive interim six-month data from its Phase 2 trial of setmelanotide in Prader-Willi Syndrome patients, showing significant improvements in BMI, body composition, and hyperphagia.

Rhythm Pharmaceuticals reported first quarter 2026 financial results, highlighting strong initial uptake for IMCIVREE in acquired hypothalamic obesity and progress in global regulatory approvals.

Rhythm Pharmaceuticals has appointed Kimberly J. Popovits as a new director and accepted the resignation of Edward T. Mathers from its Board of Directors.

Rhythm Pharmaceuticals announced a positive opinion from the European Medicines Agency's CHMP for IMCIVREE to treat acquired hypothalamic obesity.

Rhythm Pharmaceuticals reports significant revenue growth and positive clinical trial results for its lead assets, extending its cash runway for at least 24 months.

Rhythm Pharmaceuticals reports significant revenue growth for IMCIVREE and positive Phase 3 clinical trial results for setmelanotide in hypothalamic obesity, bolstering its financial position with a recent $189.2 million capital raise.

Rhythm Pharmaceuticals announces Q1 2025 financial results, highlighting increased IMCIVREE sales and positive Phase 3 data for setmelanotide in acquired hypothalamic obesity.

Rhythm Pharmaceuticals' Q3 2024 results show a 48% increase in product revenue compared to the same period last year, driven by sales of IMCIVREE.

Rhythm Pharmaceuticals filed an amendment to its June 30, 2024 quarterly report to disclose Rule 10b5-1 trading plans adopted by three company insiders.

Rhythm Pharmaceuticals saw a significant increase in product revenue in the second quarter of 2024, but ongoing research and development expenses contributed to a net loss.

Rhythm Pharmaceuticals reports significant revenue growth and pipeline advancements in its 2025 annual filing, despite continued operating losses, driven by IMCIVREE sales and promising clinical data.

Rhythm Pharmaceuticals' 2024 10-K filing highlights the company's focus on rare neuroendocrine diseases and the advancement of its MC4R agonists, including IMCIVREE, with topline data from the Phase 3 trial in acquired hypothalamic obesity expected in the second quarter of 2025.

Rhythm Pharmaceuticals' 2023 annual report highlights commercial growth of IMCIVREE, progress in clinical trials, and expansion of their pipeline with new drug candidates.

Alastair Garfield, Chief Scientific Officer at Rhythm Pharmaceuticals, reported transactions involving common stock and restricted stock units.

Jean Christophe, a Director at Rhythm Pharmaceuticals, Inc., has acquired 4,712 shares of common stock and been granted stock options.

David W.J. McGirr, a Director at Rhythm Pharmaceuticals, Inc., reported transactions involving common stock and equity awards.

Rhythm Pharmaceuticals Director Lynn A. Tetrault reported transactions involving common stock, restricted stock units, and stock options.

Stuart A. Arbuckle, a Director at Rhythm Pharmaceuticals, Inc., reported transactions involving the acquisition and disposition of company common stock and restricted stock units.

Director Jennifer L. Good of Rhythm Pharmaceuticals, Inc. reported transactions involving the acquisition and disposition of company common stock and restricted stock units.

Rhythm Pharmaceuticals will hold its annual stockholders meeting virtually on June 24, 2025, to vote on director elections, auditor ratification, executive compensation, officer exculpation, and meeting adjournment if needed.

Rhythm Pharmaceuticals is holding its annual meeting on June 24, 2025, to vote on director elections, auditor ratification, executive compensation, officer exculpation, and potential meeting adjournment.

Rhythm Pharmaceuticals will hold its annual stockholders meeting virtually on September 18, 2024, to vote on director elections, auditor ratification, executive compensation, and reapproval of the equity incentive plan.

Rhythm Pharmaceuticals is holding its Annual Meeting of Stockholders on September 18, 2024, to vote on key proposals including the election of directors, ratification of the independent auditor, executive compensation, and reapproval of the 2017 Equity Incentive Plan.

Rhythm Pharmaceuticals has postponed its 2024 annual meeting to September 18, 2024, due to a technical error in the record date used for the broker search.

Rhythm Pharmaceuticals will hold its annual stockholders meeting virtually on June 18, 2024, to vote on director elections, auditor ratification, executive compensation, and reapproval of the equity incentive plan.

Perceptive Advisors and Joseph Edelman have filed an amendment reporting a 5.1% beneficial ownership stake in Rhythm Pharmaceuticals, Inc.

Vanguard Capital Management has reported beneficial ownership of 5.02% of Rhythm Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Rhythm Pharmaceuticals Inc., reporting a 0% beneficial ownership stake following an internal corporate realignment.

PRIMECAP Management Co. has reported a 5.21% beneficial ownership stake in Rhythm Pharmaceuticals, Inc. as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, revealing a 9.3% beneficial ownership in Rhythm Pharmaceuticals Inc.

PRIMECAP Management Co. reports an updated 6.42% beneficial ownership in Rhythm Pharmaceuticals, Inc. as of September 30, 2025.